^
    Back
    Association details:
    Biomarker:ER negative
    Cancer:HER2 Positive Breast Cancer
    Drug:Herceptin (trastuzumab) (HER2 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrialsregister.eu
    Title:

    Comparison of paclitaxel, liposomal doxorubicin (and, i.a. carboplatin) with epirubicin, paclitaxel and cyclophosphamide for neoadjuvant treatment of high-risk early breast cancer Vergleich von Paclitaxel, liposomalem Doxorubicin (und ggfs. Carboplatin) mit Epirubicin, Paclitaxel und Cyclophosphamid als neodjuvante Behandlung für Hochrisikopatientinnen

    Excerpt:
    ...ER/PR negative is defined as <=1% stained cells and HER2-positive is defined as IHC 3+ or in-situ hybridization (ISH) and according to ASCO-CAP guidelines as of 2013). ...
    Trial ID:
    2014-000619-14
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS)

    Excerpt:
    ...- In IRIS-A cohort, if a patient is HR negative(ER/PR<10%), the longest diameter of invasive cancer could...
    Trial ID:
    IRIS
    More C2 evidence
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    STOP-HER2: Stopping Trastuzumab in HER2+ MBC

    Excerpt:
    ...Both estrogen receptor (ER)-positive/HER2-positive and ER-negative/HER2-positive will be eligible....
    Trial ID:
    STOP-HER2
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Stage I HER2 Positive Invasive Breast Cancer De-escalation Study(IRIS-C/D)

    Excerpt:
    ...- If a patient is HR negative(ER/PR<10%), the longest diameter of invasive cancer could...
    Trial ID:
    NCT04922008
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Trastuzumab or Lapatinib Ditosylate in Treating Women With Early Breast Cancer

    Excerpt:
    ...- Estrogen receptor-negative patients may enter the trial whether or...
    Trial ID:
    EPHOS-B
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Phase I/II Study of Neoadjuvant Lapatinib in Breast Cancer

    Excerpt:
    ...- cT2cN0 ER negative...
    Trial ID:
    NCT00450892
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    Use of Trastuzumab to Induce Increased ER Expression in ER-negative/Low, Her-2/Neu Positive Breast Cancer

    Excerpt:
    ...Standard Immunohistochemistry and Allred Scores Were to be Used to Measure the Estrogen Receptor (ER) Response Rate in Patients With ER-negative/Low, and Human Epidermal Growth Factor Receptor 2 (HER2)/Neu-positive Breast Cancer....
    Trial ID:
    NCT00726180
    Less C2 evidence
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Surg Case Rep
    Title:

    Single-dose trastuzumab monotherapy achieved pathological complete response (pCR) in a patient with HER2-positive breast cancer: a case report

    Published date:
    06/21/2023
    Excerpt:
    An 88-year-old woman...positron emission tomography-computed tomography revealed estrogen receptor-negative and HER2-positive, T1N0M0, stage I breast cancer….In this case, we encountered a patient with HER2-positive breast cancer who achieved pCR with a single-agent application and single dose of trastuzumab before surgery. It is possible that some patients with HER2-positive breast cancer will have a significant response to trastuzumab, and one option may be to consider de-escalation therapy without chemotherapy...
    DOI:
    10.1186/s40792-023-01661-4